However, for HCC patients with an advanced stage, POLD1 expression was not significantly associated with prognosis (HR=1.71, P=0.13) but predicted significantly worse outcomes for those receiving sorafenib treatment (HR=4.13, P=0.026). This evidence concerns the gene POLD1 and hepatocellular carcinoma.